Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
37.94
-0.29 (-0.76%)
Mar 9, 2026, 3:09 PM EDT - Market open
Crinetics Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 7.7 | 1.04 | 4.01 | 4.74 | 1.08 | Upgrade
|
| Revenue Growth (YoY) | 640.71% | -74.11% | -15.28% | 339.43% | 1418.31% | Upgrade
|
| Cost of Revenue | 333.13 | 240.16 | 168.53 | 130.23 | 84.26 | Upgrade
|
| Gross Profit | -325.44 | -239.12 | -164.51 | -125.49 | -83.18 | Upgrade
|
| Selling, General & Admin | 191.33 | 99.74 | 58.09 | 42.39 | 24.53 | Upgrade
|
| Operating Expenses | 191.33 | 99.74 | 58.09 | 42.39 | 24.53 | Upgrade
|
| Operating Income | -516.77 | -338.85 | -222.61 | -167.88 | -107.7 | Upgrade
|
| Interest & Investment Income | 51.99 | 41.44 | 13.44 | 4.32 | 0.16 | Upgrade
|
| Earnings From Equity Investments | - | -0.47 | -5.2 | -1.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.36 | -0.52 | -0.16 | 0.66 | 0.01 | Upgrade
|
| Pretax Income | -465.14 | -298.41 | -214.53 | -163.92 | -107.64 | Upgrade
|
| Income Tax Expense | 0.18 | - | - | - | - | Upgrade
|
| Net Income | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 | Upgrade
|
| Net Income to Common | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 | Upgrade
|
| Shares Outstanding (Basic) | 94 | 81 | 58 | 52 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 94 | 81 | 58 | 52 | 38 | Upgrade
|
| Shares Change (YoY) | 16.43% | 39.11% | 11.71% | 35.24% | 26.24% | Upgrade
|
| EPS (Basic) | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | Upgrade
|
| EPS (Diluted) | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 | Upgrade
|
| Free Cash Flow | -383.68 | -234.04 | -173.29 | -116.86 | -89.02 | Upgrade
|
| Free Cash Flow Per Share | -4.08 | -2.90 | -2.98 | -2.25 | -2.32 | Upgrade
|
| Operating Margin | -6714.77% | -32613.47% | -5547.17% | -3544.06% | -9990.91% | Upgrade
|
| Profit Margin | -6046.22% | -28720.69% | -5345.85% | -3460.38% | -9985.25% | Upgrade
|
| Free Cash Flow Margin | -4985.50% | -22525.31% | -4318.12% | -2466.98% | -8258.26% | Upgrade
|
| EBITDA | -512.88 | -336.07 | -221.51 | -166.9 | -106.78 | Upgrade
|
| D&A For EBITDA | 3.89 | 2.79 | 1.1 | 0.98 | 0.92 | Upgrade
|
| EBIT | -516.77 | -338.85 | -222.61 | -167.88 | -107.7 | Upgrade
|
| Revenue as Reported | 7.7 | 1.04 | 4.01 | - | - | Upgrade
|
| Advertising Expenses | 16.9 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.